Effects of in utero androgen excess and metformin treatment on hepatic functions

GA Abruzzese, MF Heber, MJ Ferrer…�- Molecular and cellular�…, 2019 - Elsevier
GA Abruzzese, MF Heber, MJ Ferrer, SR Ferreira, AF Silva, AB Motta
Molecular and cellular endocrinology, 2019Elsevier
This study aimed to evaluate the role of prenatal hyperandrogenization in liver functions and
the extent of metformin as treatment. Pregnant rats were hyperandrogenized with
subcutaneous testosterone (1mg/rat) between 16 and 19 of pregnancy. Prenatally
hyperandrogenized (PH) female offspring displayed, at the adult life, two phenotypes; a PH
irregular ovulatory phenotype (PHiov) and a PH anovulatory (PHanov) phenotype. From day
70 to the moment of sacrifice (90 days of age), 50% of the animals of each group received a�…
Abstract
This study aimed to evaluate the role of prenatal hyperandrogenization in liver functions and the extent of metformin as treatment. Pregnant rats were hyperandrogenized with subcutaneous testosterone (1mg/rat) between 16 and 19 of pregnancy. Prenatally hyperandrogenized (PH) female offspring displayed, at the adult life, two phenotypes; a PH irregular ovulatory phenotype (PHiov) and a PH anovulatory (PHanov) phenotype. From day 70 to the moment of sacrifice (90 days of age), 50% of the animals of each group received a daily oral dose of 50 mg/kg of metformin. We found that both PH phenotypes displayed a hepatic disruptions of insulin and glucose pathway and that metformin treatment reversed some of these alterations in a specific-phenotype manner. Our findings show, for the first time, that androgen excess in utero promotes hepatic dysfunctions and that metformin treatment is able to specifically reverse those hepatic alterations and sheds light on the possible mechanisms of metformin action.
Elsevier